Walleye Capital
CRBU icon

Walleye Capital’s Caribou Biosciences CRBU Stock Holding History

Walleye Capital’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-237,599
Closed -$466K – 4944
2024
Q3 		$466K Buy
237,599
+74,799
+46% +$153K ﹤0.01% 3357
2024
Q2 		$267K Buy
+162,800
New +$520K ﹤0.01% 4076
2023
Q4 		– Sell
-468,127
Closed -$2.24M – 5017
2023
Q3 		$2.24M Sell
468,127
-25,985
-5% -$161K 0.01% 1647
2023
Q2 		$2.1M Buy
+494,112
New +$2.22M 0.01% 1291
2021
Q4 		– Sell
-15,164
Closed -$362 – 2136
2021
Q3 		$362 Buy
+15,164
New +$371K 0.01% 931

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's CRBU Position: Q4 2024 in Review

Walleye Capital sold out of Caribou Biosciences (CRBU) in Q4 2024, closing a stake of 237,599 shares — an estimated $466K sold.

Walleye Capital first reported a position in CRBU in Q3 2021 and held it in 5 quarters. The position peaked at $2.24M in Q3 2023. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2024.

  • Walleye Capital reported no remaining Caribou Biosciences position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 237,599 Caribou Biosciences shares in Q4 2024, an estimated $466K.
  • Walleye Capital first reported a position in Caribou Biosciences in Q3 2021 and held it in 5 quarters.
  • Walleye Capital's Caribou Biosciences position peaked at $2.24M in Q3 2023.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.